Author | Matthew J. Ellis, MD, PhD | OncLive

Author | Matthew J. Ellis, MD, PhD

Articles

Dr. Ellis on Adjuvant CDK4/6 Inhibition in HR-Positive Breast Cancer

October 02, 2018

Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of precision medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses adjuvant CDK4/6 inhibition in hormone receptor (HR)-positive breast cancer.

Dr. Ellis Considers the Use of Biosimilars in Oncology

August 22, 2018

Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of Precision Medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses considerations for the use of biosimilars in oncology.

Dr. Ellis on the Entrance of Biosimilars Into the Field of Oncology

August 06, 2018

Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of precision medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the entrance of biosimilars into the field of oncology.

Dr. Ellis on Abemaciclib in HR-Positive Breast Cancer

August 01, 2018

Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of precision medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the use of abemaciclib (Verzenio) in hormone receptor-positive breast cancer.

x